Effect of physical exercise on treadmill in women with polycystic ovary syndrome
Not Applicable
Completed
- Conditions
- Polycystic ovary syndrome (PCOS)Nutritional, Metabolic, Endocrine
- Registration Number
- ISRCTN10416750
- Lead Sponsor
- Faculty of Medicine of Ribeirão Preto
- Brief Summary
2020 Results article in https://pubmed.ncbi.nlm.nih.gov/32286711/ (added 19/08/2021) 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34769797/ (added 06/09/2023)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 87
Inclusion Criteria
1. Polycystic ovary syndrome
2. Aged 18-39 years
3. BMI 18-39.9 kg/m² (normal, overweight and obesity grades I and II)
4. Do not practice regular physical activity
Exclusion Criteria
1. Presence of systemic disease that contraindicate physical activity
2. Presence of disabling musculo-skeletal disorders
3. Use of drugs that interfere with the hypothalamic-pituitary-ovarian-axis
4. Use of hormonal contraceptives
5. Smoking
6. Pregnant
7. Not available to participate in all stages of the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Alterations in telomere content, analyzed by quantitative real time polymerase chain reaction (qPCR) at the baseline and after 16 weeks of physical training for all groups. The data are expressed in relative values of 2-CT in which it is expected a difference of 0.3 between the group.
- Secondary Outcome Measures
Name Time Method Changes in the following were measured at the baseline and after 16 weeks of physical training for all groups:<br>1. Hormone concentrations and endocrine parameters, assessed by chemiluminescence<br>2. Body composition, assessed by absorptiometry method Dual Energy X-Ray absortiometry (DEXA), skin folds and bioelectrical impedance<br>3. Anthropometric indices<br>4. Epigenetic mechanisms, investigated by the Genome-Wide DNA methylation, X inactivation and the CAG repeat polymorphism within the androgen receptor gene<br>5. Quality of life, assessed using the Short Form 36 (SF-36) questionnaire<br>6. Anxiety and depression, assessed using the Hospital Anxiety and Depression Scale (HADS) questionnaire<br>7. Sexual function, assessed using the Female Sexual Function Index (FSFI)<br>8. Body image, assessed using the Body Shape Questionnaire (BSQ) and Figure Rating Scale (FRS)